Taking advantage of the World Antibiotic Awareness Week (WHO), the European BEAM alliance, representing 40 ‘Biopharmaceutical companies from Europe innovating in AntiMicrobial resistance’ research including Madam Therapeutics, released a position paper to acknowledge these efforts and to highlight the important role that small and medium-sized enterprises (SMEs) are playing as innovators.
The document lists ten (10) guidelines as to how antibacterial R&D could be revived and proposes specific support for SME-driven innovation in the AMR field. The alliance particularly demands that policymakers understand the specific nature and needs of SMEs to design effective PUSH and PULL mechanisms.
- Adequately-shaped incentive mechanisms that ultimately rewards R&D evidence
- Health Technology Assessment recognising the true value of SME innovation
- Dedicated regulatory pathways to support the specific needs of AMR projects and act as pre-qualification criteria to some PUSH/PULL incentive mechanisms
- PUSH incentives and funding mechanisms that are directed to SMEs, calibrated and accessible for SMEs in practice
- Calibrated Market Entry Rewards (MER) to ensure continuous and sustainable innovation from academics to biotech companies and to large pharma players
- R&D prizes and phase entry rewards as effective PULL mechanisms for SMEs to incentivise the most underserved indications in AMR
- Targeted tax incentives specifically addressing SMEs to incentivise private investments into AMR-focused companies and/or avoid de-prioritization
- Going beyond to exploit all possibilities for AMR from SMEs
- Support education to strengthen attractiveness of the field for R&D professionals/scientists
- Long term thinking and wisely usage of AMR innovations combined with appropriate diagnostics development